2 completed, 1 not yet recruiting. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 2, Not yet recruiting 1 |
Follow Pathalys Pharma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of PLS240 in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis PLS240, Standard of Care - Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism | Phase 3 | Not yet recruiting | Pathalys Pharma | 56 | 2026-10-30 | 2026-10-22 |
| Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2 PLS240, Placebo, Open-Label Extension PLS240 - Secondary Hyperparathyroidism, End Stage Kidney Disease | Phase 3 | Completed | Pathalys Pharma | 412 | 2023-05-15 | 2025-09-09 |
| Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-1 PLS240, Placebo, Open-Label Extension PLS240 - Secondary Hyperparathyroidism, End-stage Kidney Disease (ESKD) | Phase 3 | Completed | Pathalys Pharma | 362 | 2023-04-28 | 2025-09-09 |
Hyperparathyroidism, Secondary (3) · Kidney Failure, Chronic (2) · Renal Insufficiency, Chronic (1)
Standard of Care (1) · upacicalcet (1)
United States (3) · Bulgaria (2) · Poland (2) · Portugal (2) · Serbia (2) · Spain (2)
2023 (2)